NetworkNewsBreaks

WednesdayNov 02, 2022 10:22 am

NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Releases Financial Numbers for Q2

India Globalization Capital (NYSE American: IGC) is reporting financial results for second quarter 2023, the period ending Sept. 30, 2022. Highlights of the report include the potential shown by IGC-AD1 and TGR-63, the company’s main investigational drug assets, to suppress or ameliorate a key protein in Alzheimer’s cell lines that are responsible for Aβ plaques, a key indicator of Alzheimer’s disease. The company noted that IGC-AD1 is entering phase 2 trials designed to study the treatment of agitation in dementia resulting Alzheimer’s disease and, in preclinical trials, TGR-63 showed potential to reduce neurotoxicity in Alzheimer's cell lines. The report stated…

Continue Reading

TuesdayNov 01, 2022 2:16 pm

NetworkNewsBreaks – Florida Bitcoin & Blockchain Summit Opens Doors

The second annual Florida Bitcoin & Blockchain Summit (“FBBS”) is being held this week. The event, produced by Cutting Edge Events LLC, is scheduled for Nov. 4, 2022, in Tampa, Florida. Florida’s first blockchain-and-fintech-focused event, FBBS aims to make the state a leader in the blockchain and financial tech space. The event gathers key representatives from a broad spectrum of stakeholders, businesses, startups, political leaders, policymakers, regulators, fintech communities and evangelists. The gathering provides invaluable information for three types of participants: those new to crypto investing and fintech interested in increasing their industry knowledge; stakeholders, institutions or startups poised to…

Continue Reading

TuesdayNov 01, 2022 1:59 pm

NetworkNewsBreaks – CubCrafters Inc. Accelerates Manufacturing on High Demand Despite Supply Chain Challenges

CubCrafters, the leading designer and manufacturer of light-sport, experimental and Part 23 certified backcountry aircraft, has started a takeoff roll toward blue skies that offer the potential promise of corporate development through public investment. “It announced in July that it is taking reservations from potential investors as it awaits qualification by the U.S. Securities and Exchange Commission (‘SEC’) for a public stock listing. This news was met by immediate enthusiasm from the investment community as evidence of the expectations of the backcountry aircraft market’s continued growth,” a recent article reads. In a recent interview with The Bell2Bell Podcast, CubCrafters Vice…

Continue Reading

TuesdayNov 01, 2022 1:37 pm

NetworkNewsBreaks – Knightscope Inc. (NASDAQ: KSCP) Announces New Contracts, Indicative of Company’s Continued Reach

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), has announced five new contracts. The contracts are with companies across the United States from several different industries. According to the announcement, the companies include an Ohio-based global pharmaceutical manufacturer and distributor of medical and laboratory products, as well as a provider of performance and data solutions for healthcare facilities; two hotels — one in Tennessee and one in Washington state; a sports complex in New York; and a multifamily housing complex in Pennsylvania. The contracts call for Knightscope ASRs to patrol and provide surveillance for everything from parking lots…

Continue Reading

TuesdayNov 01, 2022 1:24 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures IRB Approval for Human Clinical Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of independent review board (“IRB”) approval for human clinical nicotine study NIC-H22-1, and that human dosing will begin soon. The 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study will be conducted in current cigarette smokers, wherein each person will visit the laboratory to be dosed three times over a period of weeks. Only one oral nicotine pouch (either DehydraTECH-nicotine; On! brand manufactured by Altria; or Zyn brand manufactured by Swedish Match) will be administered during each visit and evaluated. Predetermined questionnaires for subjective…

Continue Reading

TuesdayNov 01, 2022 12:59 pm

NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Exec to Present at Neuropsychiatric & Psychedelics Drug Development Summit

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the 5th annual Neuropsychiatric & Psychedelics Drug Development Summit. The summit runs through Nov. 2, 2022, and is being held in Boston. Cybin director of neuropharmacology Amy Reichelt, PhD, will present during the event; her presentation, titled “CYB004 — Modifications to DMT to Enhance its Therapeutic Potential,” includes an overview of the preclinical data for CYB004, Cybin’s deuterated dimethyltryptamine (DMT) program and the advantages of deuteration on its therapeutic effect. Reichelt’s presentation will begin at 1:15 p.m. ET today.“I am delighted to be…

Continue Reading

TuesdayNov 01, 2022 12:35 pm

NetworkNewsBreaks – Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) Engages IMS for Investor Communications Expertise

Hillcrest (CSE: HEAT) (OTCQB: HLRTF), a clean technology company developing transformative power conversion technologies and control system solutions for next-generation electrical systems, today announced that it has retained IMS Investor Relations (“IMS”) effective Oct. 1, 2022. According to the update, IMS will provide capital markets consulting, corporate communications and strategic investor outreach. “Hillcrest’s highly adaptive power conversion technology is at an exciting stage of growth and development, evidenced in part by our two recent strategic partnerships including a global tier 1 automotive supplier,” said Hillcrest Chief Executive Officer Don Currie. “IMS is a respected firm with proven sector experience, and…

Continue Reading

TuesdayNov 01, 2022 10:43 am

NetworkNewsBreaks – Odyssey Health Inc. (ODYY) Files for Patent Protection on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device

Odyssey Health (OTC: ODYY) has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device (“Nasal Device”). As previously announced, Odyssey’s recently completed phase I study to treat concussion successfully used Odyssey’s Nasal Device and drug combination. “We were very pleased with the functionality and performance of the Nasal Device during the phase I study and its administration of Odyssey’s PRV-002 concussion drug,” said Michael Redmond, CEO of Odyssey. “The ability to get drugs for neurological conditions delivered directly into the brain rapidly at effective levels while simultaneously having less concern for side effects…

Continue Reading

MondayOct 31, 2022 2:42 pm

NetworkNewsBreaks – Quad M Solutions Inc. (MMMM) Commences Application to Dual List on Upstream

Quad M Solutions (OTC: MMMM), a staffing company providing modern health care solution benefits, today announced that it has begun the application process for dual listing on Upstream, the next-generation trading app for digital securities and NFTs powered by Horizon Fintex (“Horizon”) and MERJ Exchange Limited (“MERJ”). According to the update, the planned dual listing is designed to provide Quad M with the opportunity to access a global, digital-first investor base that can trade using the USDC digital currency along with credit, debit, PayPal, and USD, unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in OTC-listed…

Continue Reading

MondayOct 31, 2022 1:55 pm

NetworkNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Shows Superior Performance to Other Anthracyclines, Standards of Care for GBM

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical innovator staking out its own position within the competitive field of research, having already progressed to human trials evaluating its novel glioblastoma multiforme (“GBM”) solution, known as Berubicin (or WP744). “Berubicin is a patented doxorubicin (‘Dox’) analog – an anthracycline chemotherapy agent novel in its ability to cross the blood-brain barrier to target tumors directly. Tested against Dox in cancer cells, Berubicin showed a greater capacity to destroy or damage the cancers. In models evaluating intracranial gliomas, Berubicin showed a greater capacity to prolong life than temozolomide, another standard of care for GBM,”…

Continue Reading